Conventional magnesium supplementation relies on passive diffusion in the small intestine, resulting in poor bioavailability. To address this, we developed an oxidized starch-chitosan-Mg 2+ composite gel that directs more Mg 2+ to the colon, where resistant polysaccharides are fermented to SCFAs that may actively enhance absorption. Mg 2+ incorporation increased the gel’s resistant component to 52.42 ± 0.63%. Increasing Mg 2+ from 0.5% to 2% reduced cumulative upper gastrointestinal release from 70.61 ± 0.79% to 43.62 ± 1.01% ( p < 0.05), with higher concentrations showing no further improvement. In Mg 2+ -deficient mice, the gel dose-dependently restored serum Mg 2+ to healthy levels. Comparison at equal Mg 2+ doses revealed that the polysaccharide carrier independently contributed to enhanced absorption. Mechanistically, resistant polysaccharides were associated with upregulation of SCFAs receptors (FFAR2/FFAR3/HCAR2) and Mg 2+ transporters (TRPM6/TRPM7/CNNM4), with immunofluorescence indicating TRPM7 upregulation. This work provides proof-of-concept evidence for a paradigm shift from passive supplementation to active regulation via SCFAs-associated transporter modulation.
No takes yet. Share an insight, caveat, or question.
Guo et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: